Chen Wei has been engaged in the research of new biological defense vaccines and new biological drugs for a long time, and has developed the first new biological drug "recombinant human interferon ω" for preventing SARS in China army and the first Ebola vaccine with new drug certificate in the world. ?

Chen Wei has been engaged in the research of new vaccines and biopharmaceuticals for biological defense for a long time, presided over the establishment of an innovation system and transformation base, and successfully developed the first biopharmaceuticals for virus prevention and control in China, the first national strategic reserve in China, and the first new genotype Ebola vaccine in the world. During the 2065 438+04-2065 438+05 Ebola epidemic in West Africa, he led the team to complete the clinical trial of Ebola vaccine in Africa, which was the first China vaccine to carry out clinical research abroad.

Chen Wei has been tempered by major tasks such as fighting SARS, Wenchuan disaster relief, Olympic security, aiding Africa and fighting Egypt, and has brought out an interdisciplinary and hard-working biological defense team. Won the 20 18 Military Science and Technology Innovation Group Award.

In March, 2020, the recombinant COVID-19 vaccine developed by the research team of the Academy of Military Medical Sciences led by Chen Wei began the human injection test.

academic writing

By the end of 2065438+May 2009, Chen Wei had published SCI papers in journals such as Nature Nanotechnology, with the highest impact factor of 53.2.

In June 2020, official website of China Academy of Engineering showed that Chen Wei published articles in The Lancet, The Lancet Global Health, Natural Nanotechnology and Advanced Materials as a correspondent.

According to the Capital Civilization Network from June 5438 to June 20201October, Chen Weiyi published 79 papers in Science and The Lancet, with the highest impact factor of 60.3.

Reference to the above content: Baidu Encyclopedia-Chen Wei